This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

News by the end of the month Mitzy great , yuve been right all along wiith your info so Ill go for that.

cheers GF.

Somethings brewing behind the scenes GF its a question of waiting for the right news to happen....any news on phase 2 will send these up another 30% in a day!.Hold tight.
"brewing".. geddit..?

Nice one Mitzy.

cheers Gf

Nice start to the day..Why the rise,?

Keep on buying.. everyone else is...

Cant buy any more iv bought my lot ,but thanks

Yup a nice rise so far and we want more.

cheers GF.

I thought it was at the end of the month it would rise with some good news,,is there buying now in anticipation...Jb..

Most certainly, but dont forget Jimmy news to come out on 6 or more products throughout the year.

cheers GF.

Thanks GF ill order that new Aston Martin then..

Talk of a new brokers note out soon could be a reason but I'm not 100% sure myself..

Could you please let us know what the details are in the note Mitzy.

cheers GF.

All I know is that its in the pipeline....the 100p target has been reached ...new broker note could be 200p plus I'm guessing..

Useful rise today looking good, Jb..

Looking very good.

cheers GF.

Everyones expecting major news tomorrow but I'm not sure....will have to wait and see.

Strong rise today

Hoping there is some news.

cheers GF.

Medical Marketing Int'l Group PLC
11 February 2005


For Immediate Release 11 February 2005


Co-inventor of Carboplatin joins MMI's Team to develop Ruthenium Cancer
Therapies


Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based
pharmaceutical development company today announces that it has further expanded
the collaboration between the University of Edinburgh and its wholly owned
subsidiary Oncosense. The team, headed by Prof. Peter Sadler, developing
Ruthenium anticancer complexes will now include Dr James Hoeschele - a
co-inventor of the best selling platinum based chemotherapy drug Carboplatin.


Dr James Hoeschele, an acknowledged expert in the field of anti-tumour precious
metal complexes, has over 30 years experience from working in both industry and
academia. He is named as inventor on 12 patents relating to platinum based
complexes used as chemotherapy agents and has published 50 reviewed scientific
papers on platinum based chemotherapy drugs including studies of
pharmacokinetics, biodistribution and their structure activity relationships.


Professor Peter Sadler and Dr Duncan Jodrell, the inventors of the Ruthenium
based anti-cancer drugs, have shown that certain ruthenium complexes appear to
have significant advantages over platinum-based drugs that are widely used in
the clinic. Oncosense is funding Professor Sadler's department to achieve
commercial targets in the development of Ruthenium compounds. Dr Hoeschele joins
the group to address certain key studies that will provide data to support the
clinical development program and will be published to support the eventual
marketing of the Ruthenium based drugs.


Dr James Hoeschele said; 'The data published on Ruthenium-based organometallic
compounds as anti-cancer therapeutics are very encouraging. I welcome the
opportunity to work with Prof. Peter Sadler and his research group in Edinburgh
as a part of the Oncosense team.'


Executive Chairman of MMI Group, David Best, commenting on the announcement
said: 'I am pleased that Dr Hoeschele has agreed to join the Oncosense team. We
have some very exciting developments ahead of us and it is important that we
have the appropriate expertise within the project team for these planned
studies. We are delighted with the progress made in the Ruthenium Project and
the role our partners at Edinburgh University have played. Dr Hoeschele has
considerable expertise within the development of anti-tumour precious metal
complexes and we anticipate that his contribution to the project will be
significant.'


For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk


cheers GF.

There she blows. Quite spectacular how this one jumps to life. SUPER.

cheers GF.